Antimicrobial activity and spectrum of daptomycin: Results from the surveillance program in Australia and New Zealand (2008)

Pathology

Volumn 42, Issue 5, 2010, Pages 470-473

  Bell, Jan M ^a   Turnidge, John D ^a,b   Sader, Helio S ^c   Jones, Ronald N ^c  

^a WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c JMI LABORATORIES   (United States)

Author keywords

Antibiotics; Bacteria; Daptomycin; In vitro activity; Microbiology

Indexed keywords

ANTIINFECTIVE AGENT; DAPTOMYCIN; OXACILLIN;

AUSTRALIA; DRUG EFFECTS; GRAM POSITIVE BACTERIUM; GRAM-POSITIVE BACTERIAL INFECTIONS; HEALTH SURVEY; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE; NEW ZEALAND;

ANTI-BACTERIAL AGENTS; AUSTRALIA; DAPTOMYCIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; MICROBIAL SENSITIVITY TESTS; NEW ZEALAND; OXACILLIN; POPULATION SURVEILLANCE;

EID: 77954793119     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.3109/00313025.2010.493869     Document Type: Article

References (13)

1. Sauermann R, Rothenburger M, Graninger W, Joukhadar C. Daptomycin: A review 4 years after first approval. Pharmacology 2008; 81: 79-91.
2. Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355: 653-665
3. Baltz RH. Daptomycin: mechanisms of action and resistance, and biosynthetic engineering, Curr Opin Chem Biol 2009; 13: 144-151
4. Sader HS, Fritsche TR, Jones RN. Antimicrobial activity of daptomycin tested against clinical strains of indicated species isolated in North American medical centers (2003). Diagn Microbiol Infect Dis 2005; 53: 329-332
5. Sader HS, Fritsche TR, Streit JM, et al. Daptomycin in vitro activity tested against Gram-positive strains collected from European and Latin American medical centers in 2003. J Chemother 2005; 17: 477-483
6. Biedenbach DJ, Bell JM, Sader HS, et al. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: A SENTRY Program Report (2003- 2004). Int J Antimicrob Agents 2007; 30: 143-149
7. Clinical and Laboratory Standards Institute. Methods for Dilution of Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. Approved standard M7-A8. 8th ed. Wayne, PA: CLSI, 2009.
8. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. Nineteenth Informational Supplement. M100-S19. Wayne, PA: CLSI: 2009.
9. Boucher HW, Sakoulas G. Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin Infect Dis 2007; 45: 601-608
10. Arias CA, Torres HA, Singh KV, et al. Failure of daptomycin monotherapy for endocarditis caused by an Enterococcus faecium strain with vancomycin-resistant and vancomycin-susceptible subpopulations and evidence of in vivo loss of the vanA gene cluster. Clin Infect Dis 2007; 45: 1343-1346
11. Coombs GW, Nimmo GR, Pearson JC, et al. Australian Group for Antimicrobial Resistance. Prevalence of MRSA strains among Staphylococcus aureus isolated from outpatients, 2006. Commun Dis Intell 2009; 33: 10-20.
12. Turnidge JD, Kotsanas D, Munckhof W, et al. Staphylococcus aureus bacteraemia: A major cause of mortality in Australia and New Zealand. Med J Aust 2009; 191: 368-373
13. Huggan PJ, Wells JE, Browne M, et al. Population-based epidemiology of Staphylococcus aureus bloodstream infection in Canterbury, New Zealand. Intern Med J 2010; 40(2): 117-125